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Over the last few decades, the number of cases of non-melanoma skin can-
cer (NMSC) has risen to over 3 million cases every year worldwide. Mem-
bers of the ERBB receptor family are important regulators of skin
development and homeostasis and, when dysregulated, contribute to skin
pathogenesis. In this study, we investigated leucine-rich repeats and
immunoglobulin-like domains 2 (LRIG2), a transmembrane protein
involved in feedback loop regulation of the ERBB receptor family during
NMSC. LRIG2 was identified to be up-regulated in various types of squa-
mous cell carcinoma (SCC), but little is known about LRIG2 in cutaneous
SCC (cSCC). To investigate the function of LRIG2 in cSCC in vivo, we
generated a skin-specific LRIG2 overexpressing transgenic mouse line
(LRIG2-TG) using the Tet-Off system. We employed the 7,12-dimethyl-
benz(a)anthracene/12-O-tetra-decanoylphorbol-13-acetate (DMBA/TPA)
two-stage chemical carcinogenesis model and analyzed the skin during
homeostasis and tumorigenesis. LRIG2-TG mice did not exhibit alterations
in skin development or homeostasis but showed an interaction between
LRIG2 and thrombospondin-1, which is often involved in angiogenesis
and tumorigenesis. However, during carcinogenesis, transgenic animals
showed significantly increased tumor progression and a more rapid devel-
opment of cSCC. This was accompanied by changes in the ERBB system.
After a single TPA application, inflammation of the epidermis was
enhanced during LRIG2 overexpression. In human skin samples, LRIG2
expression was identified in the basal layer of the epidermis and in hair fol-
licles of normal skin, but also in cSCC samples. In conclusion, epidermal
LRIG2 excess is associated with activated EGFR/ERBB4-MAPK signaling
and accelerated tumor progression in experimentally induced NMSC, sug-
gesting LRIG2 as a potential oncoprotein in skin.
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1. Introduction
Excessive exposure to the sun and a history of sun-
burns are often linked to an increased incidence of
malignant skin lesions (Kim and He, 2014; Rosso
et al., 1996). Every third cancer diagnosis is skin can-
cer, the most common type of cancer among Cau-
casians, with up to three million new non-melanoma
skin cancer (NMSC) cases per year worldwide (WHO,
2019). Increasing NMSC incidences demand the devel-
opment of new therapies and prophylactic measures,
as well as the optimization of screenings. NMSC arises
from keratinocytes, and can be divided into basal cell
carcinoma or cutaneous squamous cell carcinoma
(cSCC) depending on the cell type from which tumors
develop (Lapouge et al., 2011; Sanchez-Danes and
Blanpain, 2018; Tan et al., 2018). Dysregulated growth
factors and their receptors have a deep impact on
tumor initiation and progression (Witsch et al., 2010).
The epidermal growth factor receptor (EGFR,
ERBB1, HER1) plays a crucial role in human cSCC
(Rittie et al., 2007). The EGFR and the other mem-
bers of the ERBB receptor family (ERBB2-4, HER2-4)
are widely expressed in human epidermis (Hoesl et al.,
2018) and regulate key processes of epidermal home-
ostasis, including proliferation, differentiation, and cell
death. The deletion of ERBB4 in murine skin results
in decreased epidermal thickness and keratinocyte pro-
liferation (Hoesl et al., 2018). Skin-specific ERBB2
(Dahlhoff et al., 2017) and ERBB3 (Dahlhoff et al.,
2015) knockout mice have been shown to play a major
role of both receptors in NMSC promotion, and
EGFR has been shown to play a crucial role in skin
carcinogenesis (Chan et al., 2004; Dahlhoff et al.,
2011; 2012). Signaling of the ERBB receptors is con-
trolled by negative or positive feedback loops (Avra-
ham and Yarden, 2011). During pathogenic processes,
the dysregulation of those pathways can also influence
ERBB signaling in a tumorigenic manner (Dahlhoff
et al., 2012). The leucine-rich repeats and
immunoglobulin-like domains (LRIG) family com-
prises three transmembrane proteins (LRIG1-3) (Guo
et al., 2004; Holmlund et al., 2004; Nilsson et al.,
2001; Suzuki et al., 1996) involved in the regulation of
receptor tyrosine kinases (RTKs) such as the ERBB
receptors (Guo et al., 2004; Rafidi et al., 2013). LRIG
proteins have attracted attention especially due to their
potential as prognostic markers in different cancer
types (Lindquist et al., 2014). In the skin, LRIG1 is
predominantly expressed in a stem cell pool of the hair
follicle (HF) (Jensen et al., 2009), similarly to its
expression in the intestine (Powell et al., 2012) and
stomach (Choi et al., 2018), whereas LRIG2 and
LRIG3 are expressed throughout the epidermis (Karls-
son et al., 2008). LRIG1 knockout mice develop psori-
asis-like skin lesions (Suzuki et al., 2002). It has been
shown that LRIG1 promotes EGFR, ERBB2, and
ERBB3 degradation from the cell surface in a negative
feedback loop (Gur et al., 2004; Laederich et al., 2004;
Rubin et al., 2005) and that the extracellular domain
of LRIG1 decreases EGFR signaling in a paracrine
manner (Yi et al., 2011). LRIG3 opposes the function
of LRIG1 and stabilizes the ERBB receptors at the
cell surface of HEK293 cells (Rafidi et al., 2013).
Whereas tumor-suppressive functions of LRIG1 (Mao
et al., 2018) and LRIG3 (Guo et al., 2015) have been
reported in malignant glioma, LRIG2 seems to act
more as an oncoprotein (Holmlund et al., 2009; Ron-
dahl et al., 2013; Xiao et al., 2014). LRIG2 expression
correlates with poor prognosis in SCC of the cervix
and uterus, which show increased LRIG2 RNA levels
(Hedman et al., 2010). It has also been shown that
LRIG2 promotes EGFR signaling as a positive feed-
back loop in glioblastoma cells, supporting the
hypothesis that LRIG2 is acting as an oncoprotein
(Wang et al., 2009; Xiao et al., 2014; 2018). Impor-
tantly, although it is known that LRIG proteins can
promote and suppress tumor growth in a tissue-specific
manner (Hedman and Henriksson, 2007), the molecu-
lar mechanisms and their impact on tumorigenesis in
the skin are mostly unknown. The aim of this study
was therefore to investigate the function of LRIG2 in
the skin during development, homeostasis and tumori-
genesis, and in particular its impact on the ERBB sys-
tem. We consequently generated a skin-specific
transgenic (TG) mouse line overexpressing LRIG2
using the Tet-Off system. LRIG2-TG mice were viable
and showed no major phenotype during development
and homeostasis. When homeostasis was disrupted,
the overexpression of LRIG2, however, resulted in
increased inflammation, angiogenesis, tumor progres-
sion, and an early onset of cSCC, which affected the
ERBB signaling and components of the extracellular
matrix (ECM).
2. Materials and methods
2.1. Cell culture
HaCaT keratinocytes, A431, and A375 cells were pur-
chased from CLS (Cell lines service, Eppelheim, Ger-
many) no more than 4 months before the experiments
were performed. All human permanent cell lines in the
CLS cell bank have been authenticated using the STR
DNA profiling analysis. Mycoplasma testing is done
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every 6 months for all cultured cells using a myco-
plasma detection kit (PlasmoTest, InvivoGen, Tou-
louse, France). Cells were cultured in DMEM
medium (Biochrom, Berlin, Germany) and supple-
mented with 10% fetal calf serum (FCS; Biochrom),
penicillin (100 UmL1), and streptomycin
(100 µgmL1) (Biochrom) in a humidified incubator
with 5% CO2 at 37 ˚C.
2.2. Human samples
Biopsy samples of cSCC were obtained from 10
patients ranging in age from 71 to 92 years, after writ-
ten informed consent had been obtained. They were
obtained at the Department of Dermatology, Univer-
sity Hospital W€urzburg, Germany, and taken from the
following anatomical sites: cheeks (3 patients), forehead
(3 patients), nose, ear, dorsum of the hand and lower
leg (1 patient each). Eight of these patients were diag-
nosed at stage I (pT1G1: 6 patients, pT1G2: 2 patients)
and two at stage II (pT2G2 and pT2G3: one patient
each) as classified according to the 8th Edition of the
staging manual of the American Joint Committee on
Cancer (AJCC-8) (Califano et al., 2017). Skin samples
from non-diseased skin of 10 individuals served as con-
trols. Analysis of human tissue samples was approved
by the Ethics Committee of the Medical Faculty,
University of W€urzburg, Germany (reference number
#169/12) and the study methodologies conformed to
the standards set by the Declaration of Helsinki.
2.3. Mice
Mice were maintained under specific-pathogen-free
conditions and had access to water and standard
rodent diet (V1534; Ssniff, Soest, Germany) ad libitum.
C57BL/6N mice expressing the tetracycline-regulated
transcriptional transactivator (tTA) under the keratin
5 (KRT5) promoter have been originally described
previously (Diamond et al., 2000). We cloned murine
Lrig2 cDNA into the pTRE-tight vector (Clontech,
Mountain View, CA, USA) (pTRE-tight-LRIG2-TG
mouse line) or fused Lrig2 cDNA with a sequence
encoding the human influenza hemagglutinin (HA)-epi-
tope C-terminally (pTRE-tight-HA-LRIG2-TG mouse
line), and used these constructs to generate two inde-
pendent TG mouse lines by pronuclear microinjection
into zygotes of C57BL/6N mice. To obtain two inde-
pendent TG KRT5-LRIG2 mouse lines expressing
transgenic LRIG2 skin-specifically, the KRT5-tTA
mouse line was mated with either the pTRE-tight-
LRIG2- or the pTRE-tight-HA-LRIG2-TG mouse
line. Mouse strains were maintained in the C57BL/6N
background. For further studies we used the HA-
tagged TG mouse line, referred to as LRIG2-TG. To
study proliferation rates of 12-month-old mice, 10 mM
bromodeoxyuridine (BrdU; Roche, Mannheim, Ger-
many) dissolved in PBS were injected intraperitoneal
into the mice (30 mgkg1 body weight) 3 hours before
dissection.
To inhibit LRIG2-TG expression, 3 mgmL1 doxy-
cycline (Dox) [Beladox 500 mgg1, bela-pharm (Leh-
necke 793-588), Schortens, Germany] and 5% sucrose
(Sigma, Taufkirchen, Germany) was added to the
drinking water for 2 weeks.
LRIG2-TG mice and controls (Co) were dissected at
indicated time points, skin samples were fixed in 4%
paraformaldehyde (PFA; Sigma), dehydrated, and
embedded in paraffin or snap-frozen and stored at
80 °C until use. All murine experiments were
approved by the Committee on Animal Health and
Care of the local governmental body of the state of
Upper Bavaria (Regierung von Oberbayern), Ger-
many, and were performed in strict compliance with
the European Communities Council Directive (86/609/
EEC) recommendations for the care and use of labora-
tory animals.
2.4. Chemical skin carcinogenesis and TPA-
induced epidermal dysplasia
Chemical carcinogenesis was carried out according to
internationally accepted standards as described else-
where (Abel et al., 2009). For tumor initiation, the
carcinogen 7,12-dimethylbenz(a)anthracene (100 µL
DMBA dissolved in acetone, 400 nM; Sigma) was
applied once to the shaved back skin of 7-week-old
female LRIG2-TG mice and controls. Tumor promo-
tion was achieved by repeated application of the tumor
promoting agent 12-O-tetra-decanoylphorbol-13-ac-
etate (50 µL TPA dissolved in ethanol, 10 nM; Sigma)
twice a week for 24 weeks. Tumor development was
assessed weekly.
To investigate the effect of LRIG2 during early
hyperproliferative stages, shaved back skin of 9-week-
old LRIG2-TG mice and controls were exposed to a
single dose of TPA (50 µL TPA dissolved in ethanol,
10 nM; Sigma). Mice were euthanized 48 h after TPA
application. Skin samples were processed as described
above.
2.5. Co-immunoprecipitation and Western blot
analysis
Protein was extracted by using Laemmli extraction
buffer for skin samples or protein lysis buffer (0.05 M
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Hepes pH 7.5, 10% glycerol, 0.15 M NaCl, 1% Triton
X-100, 0.5 M EDTA, 0.5 M EGTA, 0.01 M NaF,
0.025 M b-glycerol phosphate, 0.01 M Na3Vo4, Phos-
phatase inhibitor cocktail; Roche) for cell lysates or
skin samples used for co-immunoprecipitation (IP)
experiments. Protein concentration was estimated by
bicinchoninic acid protein assay. About 300 µg of total
protein were used for co-IP with 1.8 µg HA-Tag anti-
body and Dynabeads Protein G (Invitrogen, Carls-
bad, CA, USA). Protein lysates were pre-cleared with
Dynabeads Protein G for 60 min at 4 °C and
immunoprecipitated with the HA-Tag antibody conju-
gated to the beads for 2 h at 4 °C. Samples were
washed and elution was done with 29 Laemmli extrac-
tion buffer by heating at 95 °C for 5 min. For Western
blot analysis, half of the co-IP eluate or 5-20 µg of
total protein were separated by SDS/PAGE, trans-
ferred to PVDF membranes (Millipore, Schwalbach,
Germany), and immunoblotted (IB) against antibodies
as indicated. For reference proteins as well as the total
proteins, to analyze the phosphorylated state, we
stripped the membranes by incubating them with a
stripping buffer [2% SDS, 62.5 mM Tris/HCl, pH 6.7
and 100 mM b-mercaptoethanol (BME)] for 40 min at
70 °C. Afterwards, membranes were washed, blocked,
and incubated with the second primary antibody. All
primary and secondary antibodies and their dilutions
are provided in Table S1. Densitometrical analysis was
done using IMAGEJ (http://rsb.info.nih.gov/ij).
2.6. Histology, immunohistochemistry, and
morphometric analysis
Skin samples were either embedded in paraffin or
snap-frozen on dry ice and embedded in Tissue-Tek
O.C.T.TM Compound (Sakura Finetek, Alphen aan den
Rijn, the Netherlands). Giemsa or hematoxylin and
eosin (H&E)-staining, immunofluorescence, and
immunohistochemistry were performed as described
previously (Hoesl et al., 2018). Giemsa and H&E-
stained sections were employed for histological analy-
sis. Immunohistochemical staining was performed for
the analysis of LRIG2 expression in human tissue
samples and the detection of proliferating cells
(MKI67 or BrdU positive). Briefly, sections were
boiled in 10 mM sodium citrate buffer (pH 6.0) for
antigen retrieval, and the endogenous peroxidase was
blocked with 3% H2O2 for 15 min. Slides were
blocked with 5% serum from the secondary antibody
host and incubated overnight at 4 °C with indicated
antibodies. After being washed in Tris-buffered saline
solution, the slides were incubated for 1 h with appro-
priate secondary biotin-conjugated antibodies followed
by 30 min incubation with streptavidin-biotin complex
(Vector Laboratories, Burlingame, CA, USA).
ImmPACT AMEC Red or DAB Peroxidase (HRP)
substrate (Vector Laboratories) were used as chro-
mogen. Counterstaining was performed with hema-
toxylin. Immunofluorescence stainings were performed
using the above protocol, but without blocking
endogenous peroxidase and without incubation with
the streptavidin-biotin complex. Additionally, the
M.O.M. Immunodetection Basic kit (Vector Laborato-
ries) was applied to murine sections if primary anti-
bodies were raised in mice. All primary and secondary
antibodies and their dilution are listed in Table S1.
For morphometric investigations, three different H&E-
or Giemsa-stained back skin sections were analyzed.
Per animal, 60 pictures covering a total length of
39.2 mm of back skin epidermis were taken with a
2009 magnification lens using a Leica DFC425C digi-
tal camera (Leica Microsystems, Wetzlar, Germany).
The area of all visible SGs was recorded with LAS soft-
ware version 3.8.0 (Leica Microsystems) and employed
to calculate the mean gland area. Epidermal thickness
was investigated on the same sections on three con-
stantly distributed measuring points per picture, result-
ing in a total of 180 measuring points per animal. To
analyze the epidermal proliferation rate, BrdU- or
MKI67-stained sections were evaluated and the total
number of epidermal nuclei and the total number of
BrdU or MKI67 positive nuclei were similarly deter-
mined on 60 images covering a length of 39.2 mm.
2.7. Gelatin zymography
Gelatin zymography was performed as described previ-
ously (Reiter et al., 2015). Briefly, protein samples
(50 µg) lysed in protein lysis buffer were separated on
an 8% acrylamide gel with 1% gelatin. Gels were incu-
bated in a renaturation-buffer (2.5% Triton X-100 in
H2O), followed by a 20 h developing step in the incu-
bation buffer (500 mM TRIS, 2 M NaCl, 50 mM CaCl2,
50 µM ZnCl2) at 37 °C, stained with Coomassie Bril-
liant Blue R, and washed with decolorizing solution
(5% methanol, 7% acetic acid). Proteinase activities
were determined by densitometrical analysis of the
inverse band intensities using IMAGEJ.
2.8. Mass spectrometry analysis
For mass spectrometry analysis reduced (8% BME)
and non-reduced protein samples of LRIG2-TG back
skin and controls were separated by SDS/PAGE. Gels
were stained with Coomassie Brilliant Blue R, and
protein bands above 300 kDa were excised. To reduce
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disulfide bonds, the gel slices were incubated in 45 mM
dithioerythritol/50 mM NH4HCO3 for 30 min at
55 °C. Free sulfhydryl groups were blocked using
0.1 M iodoacetamide in 50 mM NH4HCO3 at room
temperature for 2 9 15 min. For digestion, gel pieces
were minced and covered with 100 ng porcine trypsin
in 50 mM NH4HCO3 (Promega, Madison, WI, USA).
Peptides were separated on a C18 column (PepMap
RSLC, C18, 2 µm, 100A, 75 µm 9 50 cm; Thermo
Scientific, Rockford, IL, USA) at a flow rate of
200 nLmin1 using an EASY-nLC 1000 system
(Thermo Scientific, Rockford, IL, USA). The gradients
consisted of a 120 min ramp from 2% to 25% B
(100% acetonitrile, 0.1% formic acid) and a consecu-
tive ramp to 50% B within 10 min. Mass spectra were
acquired using a top 5 data-dependent method on an
online coupled LTQ Orbitrap XL instrument (Thermo
Scientific, Rockford, IL, USA). Spectra were searched
using MASCOT V2.4 (Matrix Science Ltd, London, UK)
and the murine subset of the UniProt database. For
evaluation of the data, SCAFFOLD V 4.1 (Proteome Soft-
ware, Inc, Portland, OR, USA) was used.
2.9. RNA expression analysis
Organs were homogenized in TRIzol reagent (Invitro-
gen, Darmstadt, Germany) for RNA isolation. 3 µg
RNA were reverse-transcribed in a final volume of
30 µL using RevertAid Reverse Transcriptase (Thermo
Scientific, Schwerte, Germany) according to the manu-
facturer’s instructions. For qualitative analysis of
mRNA expression of HA-Lrig2, reverse transcription
PCR (RT-PCR) using reagents from Qiagen (Hilden,
Germany) was performed. The final reaction volume
was 20 lL, and cycle conditions were 94 °C for 5 min
followed by 35 cycles of 94 °C for 1 min, 60 °C for
1 min, and 72 °C for 1 min. The following primers
were employed: HA-Lrig2 forward primer 50-GAGG-
CAGGCAGCCATCAGC-30 and reverse primer 50-
TCAAGCGTAGTCTGGGACG-30 and Gapdh for-
ward primer 50-TCATCAACGGGAAGCCCATCAC-
30 and reverse primer 50-AGACTCCACGACATACT-
CAGCACCG-30.
Quantitative mRNA expression analysis was per-
formed by quantitative real-time PCR (qRT-PCR)
using the StepOnePlusTM Real-Time PCR System
(Applied Biosystems, Waltham, MA, USA) and the
PowerUpTM SYBR Green Master Mix (Applied
Biosystems) according to the manufacturer’s instruc-
tions. The final primer concentration was 0.5 lM, and
the final reaction volume was 20 lL, and cycle condi-
tions were 95 °C for 2 min followed by 40 cycles of
95 °C for 15 s, 60 °C for 15 s, and 72 °C for 1 min.
Quantitative values were obtained from the threshold
cycle (CT) number, at which the increase in the signal
associated with the exponential growth of PCR prod-
ucts begins to be detected. Transcribed RNA (cDNA)
quantification was performed by using standard curves
generated with a plasmid containing the murine Lrig2
cDNA. We performed no-template control and no-RT
control assays, which produced negligible signals with
CT values that were greater than 35. Experiments were
performed in duplicates. The following primers were
used: Lrig2-Fw: 50-CACTGAAATACCTGAATTT-
GAGC-30, Lrig2-Rev: 50-TCAGTTCCAAGAACTG-
GAGATG-30.
2.10. Statistical analysis
Data are presented as mean  SEM and compared by
Student’s t-test (GRAPHPAD PRISM version 5.0 for Win-
dows; GraphPad Software, San Diego, CA, USA), and
in the case of more than two groups by ANOVA and
Tukey’s multiple comparison test. Incidence, papilloma
burden, and size were analyzed by 2-way ANOVA.
Group differences were considered to be statistically
significant if P < 0.05.
3. Results
3.1. LRIG2 is expressed in human skin cancer
To evaluate the significance of LRIG2 in human skin
homeostasis and tumorigenesis, we investigated LRIG2
expression in different human skin cell lines and tissue
samples of healthy individuals and patients with cSCC.
Western blot analysis revealed that LRIG2 expression
was significantly increased in human cSCC (A431) and
melanoma (A375) cell lines compared to human ker-
atinocytes (HaCaT) (Fig. 1A). In normal human skin
LRIG2 is predominantly expressed in the basal and
lower spinous layer of the epidermis and in HFs with
a mainly cytoplasmic pattern. In upper spinous layers,
LRIG2 is also located in nuclei. All cSCC samples (10
cSCC samples/10 LRIG2 positive cSCC samples)
revealed prominent LRIG2 expression in tumor cells
with a predominantly nuclear staining pattern
(Fig. 1B). These data indicate a role of LRIG2 during
the pathogenesis of cSCC in humans.
3.2. Overexpression of LRIG2 has no influence
on skin development and homeostasis
To investigate the function of LRIG2 in the skin, we
generated two independent skin-specific inducible
2480 Molecular Oncology 13 (2019) 2476–2492 ª 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
LRIG2 increases tumor progression C. Hoesl et al.
transgenic mouse lines. We used the Tet-Off system to
induce the overexpression at a later time, in case a
fetal overexpression turns out to be lethal. Both lines
were mated with a keratin 5 promoter (KRT5-tTA)
driver mouse line. As both mouse lines showed no
phenotype, in spite of an overexpression of Lrig2 on
RNA level (data not shown), the LRIG2 transgenic
mouse line (LRIG2-TG) with a C-terminal HA-tag
was used for all experiments described in this manu-
script. LRIG2-TG mice were viable, showed no
macroscopic phenotype, and bred in a Mendelian ratio
(Fig. S1A). RT-PCR (Fig. S1B), qRT-PCR (Fig. S1D)
and Western blot analysis (Fig. S1C) confirmed skin-
specific overexpression of the transgene. Western blots
revealed that LRIG2-TG animals treated for 2 weeks
with doxycycline (Dox+) showed no transgene expres-
sion but endogenous LRIG2 levels comparable to
those of control mice (Fig. S1E). LRIG2-TG mice
showed no altered expression of the other LRIG fam-
ily members LRIG1 and LRIG3 (Fig. S1E).
Immunofluorescence staining against the HA-tag
revealed expression of LRIG2 in the epidermis and
HFs of transgenic animals (Fig. 2A). Histologically,
LRIG2 overexpression had no effect on skin at any
time under homeostatic conditions (Fig. 2B), not even
in a long-term study (up to 12 months). While the HF
cycle was not impaired in LRIG2-TG mice, they
showed significantly more HFs in the late catagen
phase VIII compared with controls on day P18
(Fig. S4). However, these changes seem to be transient,
as such a finding could not be confirmed at any other
time point. Epidermal thickness and sebaceous gland
size showed no differences (Fig. 2C) between LRIG2-
TG animals and control littermates. In addition, epi-
dermal differentiation and proliferation rate were
unchanged in LRIG2-TG mice (Fig. S2). Since LRIG
proteins are feedback loop regulators of the ERBB
receptor family, we analyzed ERBB expression and
activation in the skin of LRIG2-TG and control mice
as well as their main target kinases mitogen-activated
protein kinase 1/2 (MAPK1/2) and RAC-alpha serine/
threonine-protein kinase (AKT), but no differences
became apparent (Fig. S3). Thus, we conclude that
LRIG2 overexpression does not influence epidermal
and HF development or homeostasis.
3.3. LRIG2 binds thrombospondin-1
To identify potential interacting partners of the trans-
membrane protein LRIG2, we performed mass
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Fig. 1. LRIG2 is expressed in human skin,
cSCC, and human skin cell lines. (A)
Western blot analysis of LRIG2
expression in HaCaT, A431, and A375
cells. TUBA1A was used as reference
protein. Densitometric analysis of LRIG2
in relation to TUBA1A reveals that LRIG2
is significantly more highly expressed in
both tumor cell lines compared with
HaCaT keratinocytes. Data are presented
as mean + SEM and were analyzed by
ANOVA and Tukey’s multiple comparison
test. ***P < 0.001. (B)
Immunohistochemical visualization of
LRIG2 expression (in red) in normal
human skin and cSCC. Micrographs are
representative for 10 cSCCs (8 patients
with stage I and 2 patients with stage II
according to AJCC-8, Califano et al., 2017,
see Materials and methods for details)
and 10 normal skin samples.
Magnification as indicated in the
micrographs.
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spectrometry analysis and co-IPs. Investigation of
LRIG2 expression in adult LRIG2-TG and control
mice under reducing and non-reducing conditions by
Western blot, revealed transgenic LRIG2 with a size
of 120 kDa. Additionally, we detected a positive signal
at 300 kDa, but only in non-reduced LRIG2-TG pro-
tein samples (Fig. S5A), which indicates the presence
of proteins interacting with LRIG2. Corresponding
bands of transgenic and control animals were analyzed
by mass spectrometry to detect potential binding part-
ners. Besides LRIG2, 40 further proteins were exclu-
sively identified in transgenic animals and were sorted
by total spectral counts of the non-reduced LRIG2-
TG protein fraction. A table of the top 20 proteins is
shown in Fig. S5B. We identified several keratins but
also two glycoproteins, laminin subunit beta-1
(LAMB1) and thrombospondin-1 (THBS1), both con-
taining EGF-like motifs that possibly interact with
LRIG2. In contrast to LAMB1, THBS1 has previously
been shown to play a role in SCC and other cancers
(Huang et al., 2017). We therefore focused on THBS1
for further studies. THBS1 was exclusively identified in
LRIG2-TG samples by four individual peptides. Cor-
responding MS spectra and probability scores are
shown in Fig. S5C,D. THBS1 has an important role in
tyrosine kinase-dependent signaling, is involved in
angiogenesis and tumorigenesis, and mediates cell-to-
cell and cell-to-matrix interactions. Immunoprecipita-
tion revealed that THBS1 binds LRIG2, suggesting
that THBS1 could be an important interaction partner
of LRIG2 (Fig. 2D). While its expression was not
increased in LRIG2-TG animals, THBS1 may be sta-
bilized by LRIG2 binding (Fig. S3). THBS1 regulates
the matrix-metalloproteinases (MMPs) 2 and 9 (Don-
nini et al., 2004), which could be essential for tumor
progression. We therefore analyzed MMP2 and
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MMP9 activity by zymography. LRIG2-TG mice
showed significantly increased levels of pro-MMP2
and active MMP2, whereas no changes of MMP9
levels were detected (Fig. 2E). In summary, we identi-
fied THBS1 as a binding partner of LRIG2 and
observed increased levels of pro- and active MMP2, an
important modulator of the ECM, in the skin of
LRIG2-TG mice.
3.4. LRIG2 has a significant impact on
progression of skin carcinogenesis
To determine whether LRIG2 affects skin tumorigene-
sis, we performed a two-stage chemical skin
carcinogenesis model with onetime application of
DMBA on the back skin of LRIG2-TG mice and con-
trol littermates causing tumor initiation followed by
TPA treatment twice a week. In both groups, the first
papillomata arose 4 weeks after DMBA treatment,
without differences in tumor incidence, papilloma bur-
den or size at this time. However, 10 weeks after
tumor initiation we noticed a less pronounced increase
of papilloma burden and papilloma size in LRIG2-TG
animals as compared with controls (Fig. 3B,C).
Instead of papillomata, LRIG2-TG mice developed a
cSCC-like phenotype on their backs, which started
6 weeks after tumor initiation (Fig. 3B). In all, 58% of
the transgenic animals but only 10% of control
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Fig. 3. Accelerated development of cSCC in LRIG2-TG mice in a chemically induced two-step model of skin tumorigenesis. (A) Macroscopic
pictures of the lower back skin of a representative LRIG2-TG animal and a control littermate at the final stage. Scale bars: 1 cm. (B) Papilloma
incidence, cSCC incidence, papilloma burden, and papilloma size of LRIG2-TG animals compared with control littermates (n = 21 Controls/ 15
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littermates were affected (Fig. 3A,B). Histological and
immunofluorescence analysis of the skin lesions
revealed a phenotype resembling human cSCC. Atypi-
cal spindle-like tumor cells arising from the epidermis
protruded into the dermis and were accompanied by
an inflammatory infiltrate (Fig. 3D). Moreover, vascu-
larization appeared to be increased, which indicates
angiogenesis (arrow, Fig. 3D). Tumors were stained
for keratin 8 (KRT8), an established marker for cSCC
in mice (Larcher et al., 1992). The staining showed
that KRT8 was highly expressed in the cSCC-like
lesions of LRIG2-TG mice, but not in the controls
(Fig. 4B). Additionally, cSCC-like lesions of transgenic
mice were poorly differentiated. In transgenic animals,
the expression of epidermal differentiation markers
[keratin 5 (KRT5), keratin 6 (KRT6), keratin 10
(KRT10), and loricrin (LOR), see Fig. 4A] in the
cSCC-like lesions decreased significantly in comparison
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Fig. 4. Epidermal differentiation during chemical induced skin tumorigenesis. (A) Immunofluorescence stainings against epidermal
differentiation markers KRT5, KRT6, KRT10, and LOR (in green) (B) Immunofluorescence staining against CDH1, VIM, and KRT8 (in green).
Cell nuclei are stained with DAPI (blue). Skin was obtained 24 weeks after initiation of chemically induced tumorigenesis. Shown are
representative pictures of control skin including papillomata or close to papillomata and of LRIG2-TG skin at the transition from epidermis to
cSCC (white dashed line). Scale bars: 50 µm.
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with the adjacent epidermis, whereas the epidermis
around the papillomata of controls was still differen-
tiated. Moreover, epithelial polarity was lost. A
decrease of epidermal E-cadherin (CDH1) and a con-
comitant increase of vimentin (VIM) expression in
the dermis indicate an enhanced tumor invasiveness,
which might refer to epithelial–mesenchymal transi-
tion (EMT) (Fig. 4B). Altogether, our data suggest
that LRIG2 has a tumor promoting function in mur-
ine skin, which results in an accelerated onset of
cSCC development.
3.5. Increased EGFR and ERBB4 expression
during tumor progression upon LRIG2
overexpression
To investigate whether the tumor promoting activity
of LRIG2 is ERBB receptor-dependent, we analyzed
the expression of the latter and respective down-
stream targets in transgenic and control skin during
two-stage skin carcinogenesis. Immunofluorescence
and Western blot analyses revealed an increased
expression of EGFR and ERBB4 in the cSCC-like
lesions of LRIG2-TG mice (Fig. 5A,B). Concomi-
tantly, the intracellular domain (ICD) of ERBB4 was
significantly increased in LRIG2-TG mice (Fig. 5A),
which indicates that the receptor undergoes regulated
intramembrane proteolysis. Thus the ICD can
translocate to the nucleus and act as transcription
factor. Additionally, phosphorylated ERBB4 and
phospho-EGFR were significantly increased in
LRIG2-TG mice compared with control littermates.
We identified increased levels of AKT and phospho-
rylated AKT, a typical downstream target of the
ERBB receptors, and phosphorylation of MAPK1/2
was significantly increased in transgenic animals com-
pared with controls (Fig. 5C). The activity of other
downstream targets such as SHC-transforming pro-
tein 1 (SHC1), signal transducer and activator of
transcription 3 (STAT3), STAT5, and GTPase Ras
proteins (RAS) was unchanged (data not shown).
The phosphorylation of phosphatidylinositol 3,4,5-
triphosphate 3-phosphatase and dual specificity pro-
tein phosphatase PTEN (PTEN) was significantly
increased, whereas total PTEN was decreased. This
implies the loss of the tumor-suppressive function of
PTEN (Fig. 5C). Western blot analysis of THBS1
and zymography analysis for MMP2 and MMP9
revealed no differences between LRIG2-TG and con-
trol animals (data not shown). In summary, these
data indicate that during tumorigenesis LRIG2
increases skin tumor progression, associated with acti-
vation of EGFR/ERBB4-MAPK signaling.
3.6. LRIG2 impairs TPA-induced epidermal
hyperplasia
Our data suggest that LRIG2 is involved in tumor
progression and accelerates tumorigenesis. To investi-
gate an early point of time we induced epidermal
hyperplasia by application of a single dose of TPA. In
comparison with control mice, the increase of epider-
mal thickness upon TPA treatment was less pro-
nounced in LRIG2-TG animals (Fig. 6A,B). These,
however, developed a more prominent neutrophil-
dominated inflammation (Fig. 6A). Western blot anal-
ysis revealed that the proinflammatory cytokine inter-
leukin-1-alpha (IL1A) was significantly increased in
LRIG2-TG mice, whereas interleukin-6 (IL6) was
unchanged (Fig. 6C,I). As previously observed in our
carcinogenesis model, ERBB4 was up-regulated in the
back skin of LRIG2-TG mice 48 h after TPA treat-
ment, but the fraction of phosphorylated ERBB4 was
reduced. The other ERBB receptors were unchanged –
with the exception of ERBB2, which exhibited higher
expression in LRIG2-TG mice compared with control
littermates after TPA treatment (Fig. 6C,F). Addition-
ally, we found increased activation of MAPK1 in
LRIG2-TG TPA-treated skin, whereas MAPK2 was
not affected (Fig. 6C,H). Importantly, PTEN expres-
sion levels were increased in LRIG2-TG mice, but
appeared to be phosphorylated and therefore inacti-
vated (Fig. 6C,G). In accordance with a less prominent
increase of epidermal thickness we found significantly
increased levels of cleaved caspase-3 (CASP3) in the
skin of TPA-treated LRIG2-TG mice than in controls
(Fig. 6C,G), whereas the proliferation rate was
unchanged (Fig. 6C,D,G). Moreover, LRIG2-TG mice
revealed a significant increase in THBS1 expression
(Fig. 6C,G) and a significant up-regulation of pro-
MMP9 (Fig. 6E). Unlike the findings under homeo-
static conditions, however, MMP2 activity was not
affected by LRIG2 overexpression due to TPA treat-
ment (Fig. 6E). In summary, LRIG2 overexpression
leads to an increased inflammatory response after TPA
treatment, which might contribute to tumorigenesis.
4. Discussion
LRIG proteins are important regulators of different
RTKs and are involved in negative and positive feed-
back loops of the ERBB receptor family (Avraham
and Yarden, 2011). LRIG1 and LRIG3 show mostly
tumor-suppressive function, whereas LRIG2 frequently
seems to act as an oncoprotein (Lindquist et al., 2014).
Increased LRIG2 expression correlates with a poorer
prognosis in patients with oligodendroglioma
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(Holmlund et al., 2009), cervical SCC (Hedman et al.,
2010), non-small cell lung cancer (Wang et al., 2014),
and glioblastoma (Wang et al., 2009). Ubiquitous
LRIG2 knockout mice were protected against glioblas-
toma, demonstrating that LRIG2 plays a crucial role
in glioblastoma initiation and progression (Rondahl
et al., 2013). It has been shown that the extracellular
domain of the transmembrane LRIG2 protein is the
part of the protein that is required to mediate the pro-
liferative effect during glioblastoma progression (Xiao
et al., 2014). This is an important finding, as the extra-
cellular domain of a protein is usually a more amen-
able drug target. Nevertheless, tumorigenic activity of
LRIG proteins is often tissue-specific (Hedman et al.,
2010; Holmlund et al., 2009; Lindquist et al., 2014)
and nothing is known about the function of LRIG2 in
the skin and skin tumorigenesis. We identified LRIG2
expression in a human keratinocyte cell line (HaCaT),
in an epidermal tumor cell line (A431), in a human
melanoma cell line (A375), and in human tissue sam-
ples of cSCC patients and normal skin. Our study
revealed increased LRIG2 expression in cancer cells
in vitro, indicating a tumorigenic function of LRIG2.
Interestingly, LRIG2 expression is mostly cytoplasmic
in normal, basal epidermis, but nuclear in more differ-
entiated epidermal layers and in cancer cells. LRIG
proteins show an altered localization in psoriasis
(Karlsson et al., 2008). The nuclear localization of
LRIG2 in our cSCC tissue samples may also indicate
a proliferative and pathogenic function.
To investigate the impact of LRIG2 during skin
development, homeostasis, and tumorigenesis in vivo,
we generated a skin-specific LRIG2-TG mouse model.
Long-term studies of the mouse line revealed no
major phenotypical changes under homeostatic condi-
tions. LRIG2 had no impact on epidermal thickness,
sebaceous gland size, epidermal differentiation or pro-
liferation. By employing proteomic analysis, we identi-
fied THBS1 as a potential binding partner of LRIG2.
THBS1 attracted our attention because of its EGF-
like motifs (Carlson et al., 2008), its function in the
modulation of the ECM, angiogenesis, and its implica-
tion in SCC and other types of cancer (Donnini et al.,
2004; Huang et al., 2017; Qian et al., 1997; Tan and
Lawler, 2009). The binding of THBS1 could be related
to an increase of pro-MMP2 and active MMP2, which
is essential for tumor cell invasion, inflammation, and
neovascularization (Hernandez-Perez et al., 2012).
Although these effects of LRIG2 have no obvious
impact on skin homeostasis, LRIG2-TG mice showed
an increased tumor progression compared with control
littermates during two-stage chemical skin carcinogen-
esis. Animals showed no differences in tumor initia-
tion, but at the end of the experiment 58% of all
LRIG2-TG mice, compared with only 10% of all con-
trols, developed skin tumors resembling human cSCC.
LRIG2-TG mice showed downward invasion of atypi-
cal cells, neovascularization, and inflammation,
accompanied by KRT8 expression and the loss of epi-
dermal differentiation markers. Additionally, the
decreased expression of CDH1 and concomitant
increase of VIM suggest an EMT (Kang and Mas-
sague, 2004; Navarro et al., 1991) in LRIG2-TG ani-
mals, a process essential for cell–cell interaction and
cSCC progression. Analysis of ERBB receptor expres-
sion revealed an increase of EGFR and ERBB4 and
their downstream targets MAPK and AKT. The
autonomous EGFR and ERBB4 receptors are impor-
tant for tissue development and homeostasis, but they
also play a major role in tumorigenesis, particularly in
skin cancer (Citri and Yarden, 2006; Holbro and
Hynes, 2004; Yarden and Sliwkowski, 2001). Addi-
tionally, we found the ICD of ERBB4 increased in
cSCC tissue samples of LRIG2-TG mice, which may
act as a transcription factor and have an important
impact on tumorigenesis (Haskins et al., 2014; Maatta
et al., 2006). Increased levels of phosphorylated
MAPK and AKT and the concomitant loss of PTEN
phosphatase activity are often observed in rapid and
aggressive tumorigenesis (Segrelles et al., 2002; Yang
et al., 2015). LRIG2 overexpression seems to influence
tumor suppressor PTEN activity, which may explain
the dramatic phenotype during skin carcinogenesis
and the absence of effects in skin homeostasis. Phos-
phorylation and thus inactivation of PTEN at residues
Ser380/Thr382/383 is significantly increased in
LRIG2-TG mice 24 weeks after initiation of chemi-
cally induced tumorigenesis (Yang et al., 2015). As the
altered molecular signaling may reflect the differences
between papillomata and cSCC tissue, we additionally
analyzed tumor initiation in the transgenic LRIG2
model. To investigate the very early tumor initiation
Fig. 5. ERBB receptor expression during chemically induced skin tumorigenesis. (A) Western blot and densitometric analysis of phosphorylated
ERBB receptors and ERBB receptors in skin samples obtained 24 weeks after initiation of chemically induced tumorigenesis. TUBA1A was
used as reference protein (n = 6). (B) Immunofluorescence staining against ERBB1-4 receptors (in green) using back skin sections from the
carcinogenesis experiment of control and LRIG2-TG mice. Scale bars: 50 µm. (C) Western blot and densitometric analysis of phosphorylated
and total downstream targets of ERBB receptors (MAPK1/2, AKT, and PTEN). GAPDH was used as reference protein (n = 6). Data are
presented as mean + SEM and were analyzed by Student’s t-test. *P < 0.05, **P < 0.01, ***P < 0.001.
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in more detail, we performed an epidermal hyperplasia
experiment with a single TPA application. LRIG2-TG
mice showed increased inflammatory cell infiltration
and neovascularization, which can be an indication for
tumor promotion and progression. These findings were
additionally confirmed by an increase of IL1A expres-
sion (Salven et al., 2002) and the up-regulation of
ERBB2 and ERBB4 in the skin of LRIG2-TG mice.
EGFR, however, was not increasingly expressed or
phosphorylated at this early stage, but the increased
expression of PTEN seems to be phosphorylated and
thus inactivated. Inactivation of PTEN plays an impor-
tant role in human cSCC development (Darido et al.,
2018; Hertzler-Schaefer et al., 2014), consequently the
loss of PTEN tumor-suppressive function might be an
important element of LRIG2-mediated tumor progres-
sion during skin cancer. Furthermore, it was shown
that THBS1 up-regulates MMP9 expression in
endothelial cells and promotes tumor cell invasion
(Qian et al., 1997). We found the expression of THBS1
and MMP9 to be increased in LRIG2-TG mice 48 h
after TPA application, assuming that THBS1 expres-
sion could be involved in LRIG2-mediated tumor initi-
ation and progression (Tan and Lawler, 2009). THBS1
may induce angiogenesis in tumors, influence tumor
cell adhesion, migration, invasion, and metastasis both
in vitro and in vivo (Tuszynski and Nicosia, 1996).
Additionally, THBS1 is expressed in tumor cells, show-
ing tumor progressive function. THBS1 also induces
auto-phosphorylation of EGFR in A431 cells (Liu
et al., 2009). The above supports a relationship with
the ERBB receptor system. The increase of inflamma-
tory cells such as macrophages and monocytes, how-
ever, may also have led to the increase of THBS1
(Lopez-Dee et al., 2011). Our findings during early
hyperproliferative stages point to a tumor-promoting
influence of LRIG2 excess. In contrast, we found no
alterations in THBS1 or MMP levels during skin car-
cinogenesis. The up-regulation of pro-MMP9 during
TPA approach and the increase of pro- and active
MMP2 may be overlaid by a general increase of
MMP2 and MMP9 in cSCC as previously described
(Dumas et al., 1999).
5. Conclusions
In conclusion, our study reveals an important function
of LRIG2 during skin carcinogenesis. In human skin,
LRIG2 is expressed in the HF and in the basal layer
of the epidermis, and our preliminary data indicate
that its expression is increased in skin cancer cell lines.
Furthermore, we detected LRIG2-positive cells as a
frequent feature of human cSCC samples. Even though
LRIG2 overexpression has no obvious major impact
on skin development and homeostasis, LRIG2 may
promote tumor growth and induce a more severe car-
cinogenic phenotype, possibly by inactivating the
tumor suppressor PTEN. Our results show an early
onset of cSCC in LRIG2-TG mice during two-stage
chemical skin carcinogenesis accompanied by altered
ERBB signaling.
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